Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Monday, November 23, 2009, 7:25PM AEST - The Australian Stockmarket is closed.
To create a watchlist or portfolio of shares,
Register
FINANCE HOME PAGE
INVESTING
FINANCE NEWS
PERSONAL FINANCE
SMALL BUSINESS
Enter symbol(s):
Symbol Lookup
|
Exchanges
Search News:
Genzyme Corp. (GENZ)
On Nov 21:
50.05 USD
0.00 (0.00%)
MORE ON GENZ
Quotes
Summary
Options
Historical Prices
Charts
Basic Chart
Technical Chart
Technical Analysis
Detailed Data
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheet
Cash Flow
Genzyme Corporation
(NasdaqNM:GENZ) Delayed quote data
Last Trade:
50.05 USD
Trade Time:
Nov 21
Change:
0.00 (0.00%)
Prev Close:
50.05
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
58.61
Day's Range:
N/A - N/A
52wk Range:
47.09 - 73.75
Volume:
0
Avg Vol
(3m)
:
3,520,820
Market Cap:
13.28B
P/E
(ttm)
:
28.53
EPS
(ttm)
:
1.75
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add GENZ to Portfolio
Download Data
HEADLINES
Wall Street's 10 Favorite Stocks Right Now
at Motley Fool
(Sat, Nov 21)
Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript
(Sat, Nov 21)
Biotech Stock Mailbag: FDA Playbook
at TheStreet.com
(Fri, Nov 20)
Now's a Great Time to Invest -- So Don't Blow It Like This
at Motley Fool
(Fri, Nov 20)
This Stock Is a Train Wreck
at Motley Fool
(Fri, Nov 20)
Genzyme: Analysts' Upgrades, Downgrades
at TheStreet.com
(Fri, Nov 20)
Genzyme's Problems Continue
Zacks.com
(Fri, Nov 20)
Zacks #5 Rank Additions for Thursday
Zacks.com
(Thu, Nov 19)
Drug Lowers Cholesterol; Stock Follows
at Motley Fool
(Thu, Nov 19)
Genzyme Drops Kidney-Drug Plans Amid Pileup of Bad News
at The Wall Street Journal Online
(Thu, Nov 19)
UPDATE - Genzyme negative news continues; stops drug trial
at Reuters
(Thu, Nov 19)
Another Genzyme Drug Goes Kaboom: BioBuzz
at TheStreet.com
(Thu, Nov 19)
[$$] Genzyme Ends Effort to Develop Stronger Version of Renvela
at The Wall Street Journal Online
(Wed, Nov 18)
More Headlines for GENZ...
ANALYST
EPS Est (next year)
(Dec-09)
:
2.27
EPS Est (in 2 years)
(Dec-10)
:
3.72
Avg Rec (current)*:
2.3
PEG Ratio:
1.01
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Genzyme Corporation operates as a biotechnology company worldwide. The companys Genetic Diseases segment manufactures and distributes therapeutic products, including Cerezyme as an enzyme replacement therapy for the treatment of Type 1 and T...
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Australia
New Zealand
US
----------------
Argentina
Austria
Brazil
Canada - Toronto
Canada - Vancouver
China - Shanghai
China - Shenzhen
Denmark
France
Germany XETRA
Germany - Berlin
Hong Kong
India - Bombay
India - National
Indonesia
Israel
Italy
Malaysia
Mexico
Netherlands
Norway
Singapore
South Korea - Korea
South Korea - KOSDAQ
Spain
Sweden
Switzerland
Taiwan OTC
Taiwan
Thailand
United Kingdom
Symbol Lookup
Latest News
7 Indices